A lack of AhR agonists may lead to a reduction in glucagon-like peptide-1 (GLP-1) and IL-22 secretion, thereby increasing intestinal permeability and exacerbating inflammation, which further worsens IBS symptoms (76). The gene discussed is GCG; the disease is irritable bowel syndrome.